Online pharma research on the rise: study

Share this article:
Three out of five pharmaceutical market research studies—60 % of those fielded in the US and abroad—were conducted online last year, a new study shows.

The results of the 2007 Medefield Pharmaceutical Market Research Trends Study shows that Internet-based market research is conducted three times more often than telephone
interviews and nearly four times as often as those performed face-to-face.

According to the study there has been solid growth in the online category. Last year's increase -- up 43 percent -- shows a sharper curve than in previous years, Medefield said.

Meanwhile, the use of face-to-face and telephone research experienced a decline, with face-to-face falling 28% and telephone interviews dropping 41% since 2006, the study showed.

Johanne Guarda SVP of Medefield America said market researchers have grown more
ambitious in recent years as they design “more complex studies with higher goals, aimed at reaching more physicians geographically, within a cross-section of specialties.”

More than 20 global pharmaceutical and biotech companies were represented in the study including AstraZeneca, Pfizer, Wyeth, Novartis, Roche and Bristol-Myers Squibb.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Judge blocks FDA bid to allow generic Precedex

Judge blocks FDA bid to allow generic Precedex

The US District Court for Maryland granted Hospira a temporary restraining order (TRO) against FDA, after the agency determined that potential generic competitors of the company's injectable sedation drug Precedex ...

GSK drug gets aplastic anemia indication

GSK drug gets aplastic anemia indication

Promacta was previously indicated for chronic immune thrombocytopenia.

Five things for Pharma Marketers to know: Wednesday, August 27

Five things for Pharma Marketers to know: Wednesday, ...

Allergan sets a shareholder voting date, Novo describes the types of acquisitions it will consider, and the AstraZeneca-Pfizer talks can now reopen.